Osborne Ryan F, Brown Jimmy J
Department of Otolaryngology-Head and Neck Surgery, Charles R. Drew University of Science and Medicine, 12021 South Wilmington Avenue, Room 5004, Los Angeles, CA 90059-3051, USA.
Surg Oncol Clin N Am. 2004 Jan;13(1):71-80. doi: 10.1016/S1055-3207(03)00117-0.
The data indicate that SCC of the various subsites of the oropharynx can be treated successfully with acceptable locoregional control and survival rates by using either surgery or primary radiotherapy for TI or T2 primary lesions. Treatment success data for late-stage disease (T3 and T4) are less encouraging. regardless of which modality is used or which treatment center is administering treatment. This finding may suggest an intrinsic property of these lesions or the patient that may be going unnoticed.One problem is that the diversity of approaches to these lesions hinders any meaningful comparisons between series from different treatment centers. There exists heterogeneity in patient populations and approaches to staging and characterization of these diseases. This situation has ensured the same heterogeneity in treatment philosophy, which is largely institutionally based.
数据表明，通过对T1或T2期原发病变采用手术或原发性放射治疗，口咽各亚部位的鳞状细胞癌能够以可接受的局部区域控制率和生存率成功治疗。晚期疾病（T3和T4）的治疗成功数据则不那么令人鼓舞，无论使用哪种治疗方式或哪个治疗中心进行治疗。这一发现可能表明这些病变或患者存在未被注意到的内在特性。一个问题是，针对这些病变的治疗方法的多样性阻碍了不同治疗中心系列之间进行任何有意义的比较。在患者群体以及这些疾病的分期和特征描述方法方面存在异质性。这种情况导致了治疗理念上同样的异质性，而这在很大程度上是以机构为基础的。
